Managed Entry Agreements in UK, Italy And Spain
نویسندگان
چکیده
منابع مشابه
Managed Entry Agreements in UK, Italy And Spain.
Stretched health care budgets and the increasing availability of high-cost medicines, together with increasing patient expectations, means that manufacturers seeking reimbursement for their products need to demonstrate more than ever that their drugs can provide value-for-money. Due to this complex environment, formal agreements between payers and manufacturers have been developed with the aim ...
متن کاملManaged entry agreements
Background New scientific progress in the “precision medicines” direction and a better diagnosis of rare diseases have led Regulators and Payers to focus their vigilance towards the real life setting. Although Regulators and Payers are taking into consideration patient pressures for rapid access to treatment, nevertheless they must balance the difficulties of taking significant decision coping ...
متن کاملWhat principles should govern the use of managed entry agreements?
BACKGROUND To ensure rapid access to new potentially beneficial health technologies, obtain best value for money, and ensure affordability, healthcare payers are adopting a range of innovative reimbursement approaches that may be called Managed Entry Agreements (MEAs). METHODS The Health Technology Assessment International (HTAi) Policy Forum sought to identify why MEAs might be used, issues ...
متن کاملPayer Vs. Industry Views on Managed Entry Agreements.
Representatives from pharmaceutical companies (n=9) were interviewed, including senior personnel from pricing, market access, health economics and outcomes research and marketing. Payer proxies from the UK, France and Italy, such as health economists and payer advisors (n=10), were also interviewed. The different types of MEAs were presented to the respondents (Figure 1) at the outset of the di...
متن کاملThe Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
BACKGROUND Managed entry agreements (MEAs) are a set of instruments to facilitate access to new medicines. This study surveyed the implementation of MEAs in Central and Eastern Europe (CEE) where limited comparative information is currently available. METHOD We conducted a survey on the implementation of MEAs in CEE between January and March 2017. RESULTS Sixteen countries participated in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2014
ISSN: 1098-3015
DOI: 10.1016/j.jval.2014.08.1204